Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470704 · ClinicalTrials.gov registry record · Phase 2
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
A Phase 2 study, sponsored by Nancy Lin, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00470704 is a Phase 2 study that has completed, run by Nancy Lin, MD. The registered enrollment target is 87 participants.
The verdict
NCT00470704, a Phase 2 study, has completed, sponsored by Nancy Lin, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
In this research study we are studying the effects of the combination of lapatinib plus Herceptin in subjects with breast cancer that has spread outside of the breast. We are also studying whether positron emission tomography (PET/CT) scans can predict which participants will benefit from the study treatment. Finally, we are studying genes and proteins in the tumor tissue that may lead to sensitivity or resistance to Herceptin, and to the combination of Herceptin plus lapatinib. Lapatinib is a compound that may stop cancer cells from growing. Other research studies suggest that lapatinib in combination with Herceptin may help to shrink or stabilize breast cancer.
Interventions
- DRUG Lapatinib
- DRUG Herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2007-05-14 |
| Est. Completion | 2024-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470704
The ClinicalTrials.gov registry entry for NCT00470704 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nancy Lin, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lapatinib is the first listed.
NCT00470704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470704 about?
NCT00470704 is a clinical study titled "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer". In this research study we are studying the effects of the combination of lapatinib plus Herceptin in subjects with breast cancer that has spread outside of the breast. We are also studying whether positron emission tomography (PET/CT) scans can predict which participants will benefit from the study ...
What is the current status of trial NCT00470704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2007-05-14. Estimated completion is 2024-08-20.
What interventions are being tested in trial NCT00470704?
The interventions under investigation include: Lapatinib (DRUG), Herceptin (DRUG).
Who is sponsoring clinical trial NCT00470704?
This trial is sponsored by Nancy Lin, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.